Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab.
Saved in:
| Title: | Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab. |
|---|---|
| Authors: | Kumar D; Department of Otolaryngology, University of Kansas Medical Center, Kansas City., Kandl C; Department of Otolaryngology, University of Kansas Medical Center, Kansas City., Hamilton CD; Department of Otolaryngology, University of Kansas Medical Center, Kansas City., Shnayder Y; Department of Otolaryngology, University of Kansas Medical Center, Kansas City., Tsue TT; Department of Otolaryngology, University of Kansas Medical Center, Kansas City., Kakarala K; Department of Otolaryngology, University of Kansas Medical Center, Kansas City., Ledgerwood L; Department of Otolaryngology, University of Kansas Medical Center, Kansas City., Sun XS; Departments of Grain Science and Industry, and Biological and Agricultural Engineering, Kansas State University, Kansas City., Huang HJ; PepGel LLC, Manhattan, Kansas., Girod D; Department of Otolaryngology, University of Kansas Medical Center, Kansas City., Thomas SM; Department of Otolaryngology, University of Kansas Medical Center, Kansas City4Department of Cancer Biology, University of Kansas Medical Center, Kansas City5Department of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City6Universi. |
| Source: | JAMA otolaryngology-- head & neck surgery [JAMA Otolaryngol Head Neck Surg] 2015 Dec; Vol. 141 (12), pp. 1133-9. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101589542 Publication Model: Print Cited Medium: Internet ISSN: 2168-619X (Electronic) Linking ISSN: 21686181 NLM ISO Abbreviation: JAMA Otolaryngol Head Neck Surg Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
